Showing results (251-260 of 367) with videos related to
Sort By:
Pageof 37
Blood|October 12, 2023
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trialDespoina Papazoglou, Xin Victoria Wang, Tait D Shanafelt, et al.Journal of Proteome Research|April 21, 2007
Large-scale identification of N-terminal peptides in the halophilic archaea Halobacterium salinarum and Natronomonas pharaonisMichalis Aivaliotis, Kris Gevaert, Michaela Falb, et al.Blood|September 28, 2011
CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101Margot Jak, Gregor G W van Bochove, Eric A Reits, et al.Pharmaceutics|December 28, 2021
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial FluidMiro Julian Eigenmann, Tine Veronica Karlsen, Marek Wagner, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 13, 2016
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCBSherri Dudal, Heather Hinton, Anna M Giusti, et al.Journal for Immunotherapy of Cancer|July 28, 2022
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumorsSophia Stock, Mohamed-Reda Benmebarek, Anna-Kristina Kluever, et al.Plos One|February 14, 2013
A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitorsMarkus Thomas, Yvonne Kienast, Werner Scheuer, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|June 8, 2023
ANG2 Blockade Diminishes Proangiogenic Cerebrovascular Defects Associated With Models of Hereditary Hemorrhagic TelangiectasiaXingyan Zhou, Jenna C Pucel, Aya Nomura-Kitabayashi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacyYvonne Kienast, Christian Klein, Werner Scheuer, et al.Journal for Immunotherapy of Cancer|July 30, 2021
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodiesGabrielle Leclercq, Hélène Haegel, Anneliese Schneider, et al.Pageof 37